Retail Employees Superannuation Pty Ltd as trustee for Retail Employees Superannuation Trust Buys Shares of 8,692 IDEXX Laboratories, Inc. $IDXX

Retail Employees Superannuation Pty Ltd as trustee for Retail Employees Superannuation Trust bought a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 4th quarter, Holdings Channel.com reports. The fund bought 8,692 shares of the company’s stock, valued at approximately $5,880,000. IDEXX Laboratories comprises approximately 1.6% of Retail Employees Superannuation Pty Ltd as trustee for Retail Employees Superannuation Trust’s investment portfolio, making the stock its 25th largest position.

Several other hedge funds have also recently added to or reduced their stakes in the business. Virtus Advisers LLC acquired a new stake in shares of IDEXX Laboratories during the 3rd quarter worth about $26,000. Park Place Capital Corp acquired a new stake in shares of IDEXX Laboratories during the 4th quarter worth about $29,000. WealthCollab LLC acquired a new stake in shares of IDEXX Laboratories during the 2nd quarter worth about $30,000. Greykasell Wealth Strategies Inc. acquired a new stake in shares of IDEXX Laboratories during the 3rd quarter worth about $35,000. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in shares of IDEXX Laboratories during the 3rd quarter worth about $36,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, EVP Nimrata Hunt sold 1,758 shares of the firm’s stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $634.57, for a total value of $1,115,574.06. Following the sale, the executive vice president directly owned 18,141 shares of the company’s stock, valued at approximately $11,511,734.37. This trade represents a 8.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.79% of the company’s stock.

IDEXX Laboratories Price Performance

IDXX opened at $550.99 on Thursday. The company’s 50 day simple moving average is $565.23 and its 200 day simple moving average is $638.69. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. IDEXX Laboratories, Inc. has a 1 year low of $504.56 and a 1 year high of $769.98. The stock has a market capitalization of $43.46 billion, a PE ratio of 40.57, a P/E/G ratio of 3.24 and a beta of 1.58.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The business had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.12 billion. During the same period last year, the company earned $2.91 earnings per share. The company’s quarterly revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, sell-side analysts expect that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

Analysts Set New Price Targets

Several research firms have issued reports on IDXX. Barclays decreased their price target on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. Citigroup began coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target on the stock. UBS Group decreased their price target on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 28th. Piper Sandler decreased their price target on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research note on Monday, February 9th. Finally, Weiss Ratings cut shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Seven analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $751.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.